Multi-criteria decision analysis of value evaluation of rare disease medical insurance drugs in China. [PDF]
BMC Public HealthChen K +6 more
europepmc +1 more source
From co-creation to compounding value: A new model of rare disease science communication in China. [PDF]
Intractable Rare Dis ResChen Y.
europepmc +1 more source
G protein-coupled receptors in prostate cancer: research progress and therapeutic targets. [PDF]
Front Cell Dev BiolXiong W, Zhou B, Shi J, Ni D, Xiong Z.
europepmc +1 more source
International Journal of Rare Diseases & Disorders, 2018 Nuijten Mark, Fugel Hans Joerg, Vis Jan
openaire +1 more source
Advances in Cell and Gene Therapy for Rare Disease Treatment. [PDF]
Int J Stem CellsBaek HJ, Nam Y, Rim YA, Ju JH.
europepmc +1 more source
Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands. [PDF]
Int J Technol Assess Health CareVersteeg JW +5 more
europepmc +1 more source
How to evaluate rare disease policy effectiveness based on policy modeling consistency (PMC) index model: A quantitative assessment of policy implementation in China. [PDF]
Intractable Rare Dis ResZhao Y +6 more
europepmc +1 more source
HTA Evidence in Rare Diseases: Just Rare or Also Special? [PDF]
PharmacoeconomicsBasu A +3 more
europepmc +1 more source
Strategic Drivers Behind Early Withdrawal of Orphan Designations in the EU: A Retrospective Analysis (2000-2024). [PDF]
Ther Innov Regul SciBouwman L, Castanheira M, Siotis G.
europepmc +1 more source
Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies. [PDF]
DiseasesAfonso S +6 more
europepmc +1 more source